4.8 Article

A growth-factor-activated lysosomal K+ channel regulates Parkinson's pathology

Journal

NATURE
Volume 591, Issue 7850, Pages 431-+

Publisher

NATURE RESEARCH
DOI: 10.1038/s41586-021-03185-z

Keywords

-

Funding

  1. NIH [1 R01 GM133172, 1 R01 HL147379, NS088322, R01 NS115139, P50 NS053488, U19-AG062418]
  2. Parker Family Chair
  3. National Natural Science Foundation of China [81925012]
  4. Newton Advanced Fellowship [NAF_R1_191045]
  5. NIH centre [P30DK050306, P30DK019525, P30CA016520]
  6. Michael J. Fox Foundation for Parkinson's Research
  7. Abbvie
  8. Allergan
  9. Amathus therapeutics
  10. Avid Radiopharmaceuticals
  11. Biogen
  12. BioLegend
  13. Bristol-Myers Squibb
  14. Celgene
  15. Denali
  16. GE Healthcare
  17. Genentech
  18. GlaxoSmithKline
  19. Golub Capital
  20. Handl Therapeutic
  21. Insitro
  22. Janssen Neuroscience
  23. Lilly
  24. Lundbeck
  25. Merck
  26. Meso Scale Discovery
  27. Pfizer
  28. Piramal
  29. Prevail Therapeutics
  30. Roche
  31. Sanofi Genzyme
  32. Servier
  33. Takeda
  34. Teva
  35. UCB
  36. Verily
  37. Voyager Therapeutics

Ask authors/readers for more resources

This study uncovers a pathway by which extracellular growth factors regulate intracellular organelle function, and establishes a targetable mechanism by which common variants of TMEM175 confer risk for Parkinson's disease. The TMEM175 gene's common variants can increase or decrease the risk of developing Parkinson's disease, affecting neuronal damage and defense capabilities.
Lysosomes have fundamental physiological roles and have previously been implicated in Parkinsons disease(1-5). However, how extracellular growth factors communicate with intracellular organelles to control lysosomal function is not well understood. Here we report a lysosomal K+ channel complex that is activated by growth factors and gated by protein kinase B (AKT) that we term lysoK(GF.) LysoK(GF) consists of a pore-forming protein TMEM175 and AKT: TMEM175 is opened by conformational changes in, but not the catalytic activity of, AKT. The minor allele at rs34311866, a common variant in TMEM175, is associated with an increased risk of developing Parkinsons disease and reduces channel currents. Reduction in lysoK(GF) function predisposes neurons to stress-induced damage and accelerates the accumulation of pathological alpha-synuclein. By contrast, the minor allele at rs3488217another common variant of TMEM175, which is associated with a decreased risk of developing Parkinsons diseaseproduces a gain-of-function in lysoK(GF) during cell starvation, and enables neuronal resistance to damage. Deficiency in TMEM175 leads to a loss of dopaminergic neurons and impairment in motor function in mice, and a TMEM175 loss-of-function variant is nominally associated with accelerated rates of cognitive and motor decline in humans with Parkinsons disease. Together, our studies uncover a pathway by which extracellular growth factors regulate intracellular organelle function, and establish a targetable mechanism by which common variants of TMEM175 confer risk for Parkinsons disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available